RxDoctor Payments Data

Toni Johnson, NP

Nurse Practitioner · Stockbridge, GANPI 1871059097

Payments from drug & device makers

$4,055in general payments, 2019–2025

Across 179 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$489
  • AstraZeneca$382
  • Merck$277
  • Seagen Inc.$191
  • Incyte Corporation$190
  • Daiichi Sankyo Inc.$189
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$3,91396%
  • Education$1424%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,055 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$41,154
Medicare patients
136
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$10,905
Anastrozole60$1,105
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine20$516
Letrozole11$323
Tamoxifen Citrate12$295
Mirtazapine26$205
Dexamethasone11$167
Olanzapine17$166
Tramadol Hcl26$105
Gabapentin26$91
Alendronate Sodium17$77
Potassium Chloride24$66
Escitalopram Oxalate11$65
Trazodone Hcl12$13

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$177$10,90517 claims
Lilly USA, LLCOlanzapine$44$16617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →